Ginkgo Bioworks is a biotechnology company that focuses on the design and engineering of microbial strains for various applications across diverse industries, including pharmaceuticals, agriculture, and industrial biotechnology. By leveraging advanced genetic engineering and synthetic biology techniques, Ginkgo aims to create custom organisms that can produce valuable ingredients, enhance agricultural yields, or contribute to sustainable manufacturing processes. The company operates through a platform model, allowing collaborations with partners to transform biological systems into efficient and scalable solutions that address real-world challenges, all while paving the way for a future with more sustainable and tailored biological products.
Many innovative firms forge strategic alliances with organizations in related sectors, much like Dyadic International Inc. (NASDAQ: DYAI) has done. One notable collaboration for the company is with Future of Foods, affiliated with the Bezos Earth Fund. News has surfaced that Future of Foods will play a significant role at the upcoming Future Food Tech conference, focusing on enhancing sustainable and healthy food ecosystems.
bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network. The Network, launched today, is a groundbreaking ecosystem of cutting edge technology partners, committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs.
Artificial Intelligence (AI) technology is disrupting many industries. One of those is healthcare and specifically the biomedical space. Data Bridge Market Research reported in 2022 that the healthcare-related AI market was expected to grow at a CAGR of 51.37% and hit a valuation of $175.22 billion by 2029. Here is a look at some of the biomedical firms that are getting attention at this point.
San Diego, CA -- (SBWIRE) -- 04/25/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Ginkgo Bioworks Holdings, Inc..
NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors C3.ai, Inc. (NYSE: AI), Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), and Polished.com, Inc. (NYSEAmerican: POL) on behalf of long-term stockholders. More information about each potential case can be found at the link provided.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Ginkgo Bioworks Holdings, Inc. (NYSE: DNA).
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) on behalf of long-term stockholders following a class action complaint that was filed against Ginkgo Bioworks with a Class Period from May 11, 2021 to October 5, 2021. Our investigation concerns whether the board of directors of Ginkgo Bioworks have breached their fiduciary duties to the company.
Consolidated net revenue increased 23% in Full Year 2022 compared to Full Year 2021; on a constant currency basis consolidated net revenue increased 28% in Full Year 2022 compared to Full Year 2021
The modern version of the Cold War Space Race has implications for scientific discovery and satellite communications. Intuitive Machines is in the thick of it.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Soaring Eagle Acquisition Corp., which merged with Ginkgo Bioworks Holdings Inc. ("Ginkgo" or "the Company") (NYSE: DNA) on September 17, 2021. Such investors who continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/dna.
San Diego, CA -- (SBWIRE) -- 02/01/2023 -- An investigation was announced for investors of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) shares over potential securities laws violations by Ginkgo Bioworks Holdings, Inc.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) on behalf of long-term stockholders following a class action complaint that was filed against Ginkgo Bioworks with a Class Period from May 11, 2021 to October 5, 2021. Our investigation concerns whether the board of directors of Ginkgo Bioworks have breached their fiduciary duties to the company.
NEW YORK, July 26, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Zymergen Inc. (NASDAQ: ZY) (“Zymergen”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”).
BALA CYNWYD, Pa., July 25, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
San Diego, CA -- (SBWIRE) -- 04/13/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Ginkgo Bioworks Holdings, Inc.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a new supply agreement expanding the depth and breadth of the collaboration between two of the leading organizations in the synthetic biology ecosystem. The four-year agreement includes an increased commitment by Ginkgo to purchase products from Twist, with the option to access significantly more synthesis capacity to meet Ginkgo’s anticipated growth. The partnership builds on a previous supply agreement signed in 2017.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ginkgo Bioworks Holdings Inc. (“Ginkgo” or the “Company”) ( NYSE: DNA; SRNG) (f/k/a Soaring Eagle Acquisition Corp.) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Owlet between May 11, 2021, and October 5, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/dna.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) (NYSE: DNA) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Ginkgo securities between May 11, 2021 and October 5, 2021, both dates inclusive (the “Class Period”). Investors have until January 18, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Los Angeles - (NewMediaWire) - January 14, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. (“Ginkgo” or “the Company”) (NYSE: DNA, NASDAQ: SRNG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Ginkgo Bioworks Holdings, Inc. (“Ginkgo”) (NYSE: DNA) f/k/a Soaring Eagle Acquisition Corp. (NASDAQ: SRNG). The action charges Ginkgo with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects. As a result of Ginkgo’s materially misleading statements to the public, Ginkgo investors have suffered significant losses.
Los Angeles - (NewMediaWire) - January 12, 2022 - The Schall Law Firm, a national shareholder rights litigation
firm, reminds investors of a class action lawsuit against Ginkgo
Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. (“Ginkgo” or
“the Company”) (NYSE: DNA,
NASDAQ: SRNG) for violations of §§10(b)
and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated
thereunder by the U.S. Securities and Exchange Commission.
Los Angeles - (NewMediaWire) - January 11, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. (“Ginkgo” or “the Company”) (NYSE: DNA, NASDAQ: SRNG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
